LifeWatch AG

EANS-Adhoc: LifeWatch Announces New "AF TeleClinic"

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide   distribution. The issuer is solely responsible for the content of this   announcement. --------------------------------------------------------------------------------@@end@@

New Products/LifeWatch AG

11.05.2010

First in Series of Treatment-Specific Remote Patient Monitoring Services

Chicago, IL / USA May 11 2010 - LifeWatch Services, Inc., a subsidiary of LifeWatch AG (SIX Swiss Exchange: LIFE), will unveil its advanced AF TeleClinic service offering this week at the Heart Rhythm Society (HRS) Annual Meeting taking place in Denver, Colorado. The AF TeleClinic service, empowered with the latest communication, IT and medical technologies, ensures physicians are well equipped to deliver optimal diagnostic and treatment options to their patients. Featuring robust reporting options with key charting metrics, and a comprehensive suite of workflow and data management tools for monitoring Atrial Fibrillation patients, the AF TeleClinic aims to improve the standards of care and clinical outcomes. The timely and accurate reporting features of the AF TeleClinic can facilitate better treatment options that improve a patient's quality of life, and reduce unnecessary and costly hospital readmissions and emergency room visits. Physicians further benefit from built-in processes designed to streamline their practice workflows and provide staffing efficiencies.

Atrial fibrillation, a disorder found in about 2.2 million Americans, is a major cause of strokes in the U.S. Approximately 15 percent of strokes occur in people with atrial fibrillation, and the likelihood of developing this condition increases with age. Three to five percent of people over 65 have atrial fibrillation. LifeWatch first addressed this condition with its unique AF Patient Care monitoring program in 2008.

"In evaluating the best solution for monitoring of our patients being treated for Atrial Fibrillation, we selected the LifeWatch AF patient care program which provides efficient patient scheduling and enhanced arrhythmia reporting options", stated Vivek Reddy, MD, FHRS, FACC Director, Cardiac Arrhythmia Service, The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology

Building on this highly successful program, LifeWatch designed the AF TeleClinic with more advanced features and benefits that conform to the new standards of practice and care for AF post procedure follow up monitoring as recommended by the HRS consensus statement, including:

* AF Ablation * Drug Titration Therapy * Cardioversion

The timesaving and cost-effective features of the AF TeleClinic include automatic scheduling of patient follow up monitoring, powerful reporting formats providing additional important data, metrics and trending charts. For instance, an advanced "Afib" report generates test-to-test serial comparative metrics for validation of procedures, treatment success and efficacy. The seamless data management and workflow algorithms increase staffing efficiencies and free up time for non-administrative patient care duties that are more critical.

The AF TeleClinic "first in the industry" bundled telemedicine service, will be followed by a series of disease-specific monitoring TeleClinics that LifeWatch is developing. Each LifeWatch TeleClinic will provide a safe and effective care model outside of the costly in hospital model. The integration of colliding technologies like remote patient monitoring services, wireless communication platforms, wearable technologies and Electronic Medical Records (EMR) serves to proactively reduce LOS (Length of Stay) for patients in the hospital and prevent unnecessary readmissions due to minor follow up situations like compliance and false alarms. The use of advanced and agnostic technologies will enable LifeWatch to collaborate with any provider in the development of successful service models that ensure the safety and well-being of patients in a timely manner.

"The launch of our first TeleClinic service offering is an exciting opportunity which directly supports the emerging health care reform initiatives in the U.S. " declared Brent Cohen, CEO, LifeWatch AG. "As a pioneer in telemedicine, LifeWatch has a strong commitment to develop advanced and cutting edge technologies that improve patient outcomes, reduce the costs of care, and deliver valuable time management processes that physicians need".

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home SleepTesting of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For additional information, please visit www.lifewatch.com and www.nitewatchservices.com.

Sign-up for customized E-mail alerts and documentation requests is available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.  THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LifeWatch AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Woo Kim, Senior Vice President of Strategy and Business Development, LifeWatch
Tel +1 847 813 4299 | Fax +1 847 813 24 48 | Email wkim@lifewatch.com

Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

Branche: Healthcare Providers
ISIN:      CH0012815459
WKN:        1281545
Index:    SPI, SPIEX
Börsen:  Frankfurt / Open Market / XETRA
              SIX Swiss Exchange / Hauptsegment
              Berlin / free trade



Weitere Meldungen: LifeWatch AG

Das könnte Sie auch interessieren: